Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

BACKGROUND AND AIMS: Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis [UC]. The purpose of this review...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Ferdinando, Magro, Fernando, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228886/
https://www.ncbi.nlm.nih.gov/pubmed/34791103
http://dx.doi.org/10.1093/ecco-jcc/jjab206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228886/
https://www.ncbi.nlm.nih.gov/pubmed/34791103
http://dx.doi.org/10.1093/ecco-jcc/jjab206

Ejemplares similares